Skip to main content
Annals of Intensive Care logoLink to Annals of Intensive Care
. 2023 Sep 29;13:95. doi: 10.1186/s13613-023-01194-x

Correction: Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial

Sylvie Chevret 1, Lila Bouadma 2,3, Claire Dupuis 3,4, Charles Burdet 3,5, Jean‑Francois Timsit 2,3,; the COVIDICUS RCT group
PMCID: PMC10541350  PMID: 37773550

Correction: Annals of Intensive Care (2023) 13:75 https://doi.org/10.1186/s13613-023-01168-z

In the original version of this article [1], the given and family names of the authors were swapped as Chevret Sylvie, Bouadma Lila, Dupuis Claire, Burdet Charles and Timsit Jean‑Francois. The corrected author names should read as Sylvie Chevret, Lila Bouadma, Claire Dupuis, Charles Burdet and Jean‑Francois Timsit. The original article has been corrected.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Reference

  • 1.Chevret S, Bouadma L, Dupuis C, Burdet C, Timsit J-F, the COVIDICUS RCT group Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial. Ann Intensive Care. 2023;13:75. doi: 10.1186/s13613-023-01168-z. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of Intensive Care are provided here courtesy of Springer-Verlag

RESOURCES